All
Blood Cancer Therapies May Play a Role in Treating COVID-19
May 7th 2020In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients,” Drs. Zainab Shahid, Farukh Awan and Ian Flinn addressed clinical trials that are underway to assess therapeutic approaches to COVID-19, including what role BTK inhibitors might play in treating the virus.
One Cancer Organization's Observations on the Impact of COVID-19 on the Blood Cancer Community
May 6th 2020In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients”, Dr. Lee Greenberger addresses steps that the Leukemia and Lymphoma Society have taken to help patients with blood cancer during the COVID-19 pandemic.
How Patients With Blood Cancers Can Boost Immune Systems to Fight Infections Like COVID-19
May 6th 2020In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients,” Drs. Ian Flinn and Farrukh Awan addressed what patients with blood cancers could do to help boost their immune systems to help prevent infections such as COVID-19, and the risk for patients who are several years removed from receiving a stem cell transplant.
FDA's Trodelvy Approval a 'Big Win' for Patients with Metastatic Triple-Negative Breast Cancer
May 6th 2020The Food and Drug Administration’s recent approval of the first antibody-drug conjugate to treat patients with pretreated metastatic triple-negative breast cancer is a major milestone, according to one expert.
FDA's Approval of Pemazyre a 'Huge Milestone' for Patients with Cholangiocarinoma
May 5th 2020The Food and Drug Administration’s recent approval of Pemazyre (pemigatinib) is a ‘huge milestone’ for patients with cholangiocarcinoma, according to the advocacy coordinator with the Cholangiocarcinoma Foundation.
Lynparza Improves Outcomes in Metastatic Prostate Cancer That Has DNA Repair Defects
May 5th 2020The PARP inhibitor Lynparza improves survival and delays disease progression in men with metastatic castration-resistant prostate cancer that expresses certain gene mutations inhibiting DNA repair, a study shows.
COVID-19's Impact on CLL, Myeloma Clinical Trials
May 5th 2020In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients”, Dr. Ian Flinn and Dr. Saad Usmani how the new coronavirus has affected stem cell transplantations as well as the management of chronic lymphocytic leukemia and myeloma clinical trials.
COVID-19's Impact on How Patients with CLL, Myeloma Have Received Treatment
May 4th 2020In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients”, Dr. Farukh Awan addresses how the new coronavirus has impacted patient care for those diagnosed with chronic lymphocytic leukemia and myeloma.